Long-Term Follow-Up Results of Topical Imiquimod for High-Grade Cervical Intraepithelial Neoplasia in Young Women: An Original Research

Why It Matters

The findings provide a fertility‑preserving alternative to excisional procedures that are linked to adverse pregnancy outcomes, potentially reshaping management of high‑grade CIN in young women. This could reduce surgical burden and improve reproductive health outcomes.

Key Takeaways

• 96% regression after 8 weeks of imiquimod.
• HPV cleared in 47% after treatment, 56% long term.
• Only 1% required invasive cervical therapy.
• CIN2 patients without HPV16/18 showed 96.5% regression.
• Imiquimod may postpone excision for up to one year.

Pulse Analysis

Topical imiquimod is emerging as a non‑surgical option for high‑grade cervical intraepithelial neoplasia (CIN 2/3), a condition traditionally managed with excisional procedures that can compromise future pregnancies. Prior trials, such as TOPIC‑3, failed to demonstrate consistent efficacy, prompting researchers to focus on younger, nulliparous women who stand to lose the most from operative interventions. By targeting patients under 35 who have not yet undergone cervical surgery, the recent study isolates a demographic where preserving cervical integrity directly translates to better obstetric outcomes.

The study’s results are striking: 96% of participants experienced lesion regression after an eight‑week course of weekly imiquimod, and nearly half cleared high‑risk HPV at the same checkpoint. Over a year of follow‑up, more than 80% achieved complete remission, while HPV clearance rose to 56% and invasive therapy was required in only 1% of cases. Notably, women with CIN 2 lacking HPV 16 or 18 showed the highest regression rate (96.5%), underscoring the importance of viral genotype in treatment response. These efficacy signals compare favorably to the morbidity associated with loop electrosurgical excision or cold‑knife conization, which carry documented risks of preterm birth and cervical insufficiency.

If validated in larger, randomized trials, imiquimod could become a first‑line, fertility‑preserving strategy for young women with high‑grade CIN, shifting clinical guidelines toward medical management. Such a shift would reduce operating‑room costs, minimize patient recovery time, and align with broader public‑health goals of lowering surgical complications. Moreover, the ability to delay excision for up to a year offers clinicians a valuable window to monitor HPV dynamics and tailor interventions, potentially improving long‑term cervical health while safeguarding reproductive plans.